Search results
Results from the WOW.Com Content Network
The Biomedical Advanced Research and Development Authority (BARDA) is a U.S. Department of Health and Human Services (HHS) office responsible for the procurement and development of medical countermeasures, principally against bioterrorism, including chemical, biological, radiological and nuclear (CBRN) threats, as well as pandemic influenza and emerging diseases.
The primary portion of the bill dealing with this office is Section 102. Among other things, the bill requires the Assistant Secretary for Preparedness and Response, with respect to overseeing advanced research, development, and procurement of qualified countermeasures, security countermeasures, and qualified pandemic or epidemic products, to: [1]
Project BioShield Act of 2004; Long title: An Act To amend the Public Health Service Act to provide protections and countermeasures against chemical, radiological, or nuclear agents that may be used in a terrorist attack against the United States by giving the National Institutes of Health contracting flexibility, infrastructure improvements, and expediting the scientific peer review process ...
BARDA, a division of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR), works to support the development of medical countermeasures such as vaccines, drugs, and diagnostic tools to counteract health security threats.
Life-threatening bleeding. Bleeding results in nearly one-third of deaths from traumatic injuries, which represent the top cause of death for people younger than 44 years in the U.S. A program ...
The AOL.com video experience serves up the best video content from AOL and around the web, curating informative and entertaining snackable videos.
Medical countermeasures (MCMs) are products such as biologics and pharmaceutical drugs that can protect from or treat the effects of a chemical, biological, radiological, or nuclear (CBRN) attack, or in the case of public health emergencies. MCMs can also be used for prevention and diagnosis of symptoms associated with CBRN attacks or threats.
The shift is taking place under the watch of Dr. Andrew Kolodny, who took over as Phoenix House’s chief medical officer a little more than a year ago. From 2003 to 2006, Kolodny worked for New York City’s health department, during which time he sought to increase access to buprenorphine as a way to reduce overdose deaths.